Safety and Efficacy Findings From the Open-Label, Multicenter, Phase 3b, Expanded Treatment Protocol Study of Ruxolitinib for Treatment of Patients with Polycythemia Vera Who Are Resistant/Intolerant to Hydroxyurea and For Whom No Alternative Treatments are Available

Focusing on patients with polycythemia vera who were hydroxyurea-resistant/intolerant patients and ineligible for clinical trials, a phase 3b, expanded treatment protocol study demonstrated that ruxolitinib is safe and effective for this patient population. The study reported >50% spleen reduction was achieved in 86.7% of patients, and dose adjustment/interruption due to adverse events occurred in 37.9% and study drug discontinuation in 8.7% of patients.

Leukemia & Lymphoma